High-Field MRI Iron-Based Contrast-Enhanced Characterization of Multiple Sclerosis and Demyelinating Diseases
Status:
Withdrawn
Trial end date:
2018-09-01
Target enrollment:
Participant gender:
Summary
Feraheme (ferumoxytol) is FDA-approved for iron supplementation and is composed of iron oxide
nanoparticles classified among the ultra-small superparamagnetic iron oxides (USPIO). In this
project we hypothesize that Feraheme could become a sensitive and specific marker of active
inflammation in multiple sclerosis. We will explore this hypothesis taking advantage of ultra
high field strength (7T) MRI to further increase the effectiveness of the contrast agent
Feraheme at revealing inflammatory activity.